{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:02:31Z","timestamp":1789830151075,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,19]]},"DOI":"10.7759\/cureus.116535","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:15:03Z","timestamp":1789827303000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Antibiotics: Bacteriophage Therapy Against Multidrug-Resistant Pathogens in the Era of Antimicrobial Resistance"],"prefix":"10.7759","author":[{"given":"Benny Vijayanandh","family":"Avanigadda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Krishna","family":"Venigalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renusri","family":"Ede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranathi Reddy","family":"Jetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkataramana","family":"Kandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun Kumar","family":"Suvvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022, 399:629-55. 10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic N","year":"2025","unstructured":"Macesic N, Uhlemann AC, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. Lancet. 2025, 405:257-72. 10.1016\/S0140-6736(24)02081-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100992","article-title":"Addressing urgent priorities in antibiotic development: insights from WHO 2023\u00a0antibacterial clinical pipeline analyses","volume":"6","author":"Melchiorri D","year":"2025","unstructured":"Melchiorri D, Rocke T, Alm RA, Cameron AM, Gigante V. Addressing urgent priorities in antibiotic development: insights from WHO 2023\u00a0antibacterial clinical pipeline analyses. Lancet Microbe. 2025, 6:100992. 10.1016\/j.lanmic.2024.100992","journal-title":"Lancet Microbe"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-026-12537-9","article-title":"Phage as a prospective arsenal against superbugs","volume":"53","author":"Zhao L","year":"2026","unstructured":"Zhao L, Wan Y, Leung SS, Yang X, Zeng P. Phage as a prospective arsenal against superbugs. Mol Biol Rep. 2026, 53:1345. 10.1007\/s11033-026-12537-9","journal-title":"Mol Biol Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13090870","article-title":"A comprehensive review on phage therapy and phage-based drug development","volume":"13","author":"Cui L","year":"2024","unstructured":"Cui L, Watanabe S, Miyanaga K, et al.. A comprehensive review on phage therapy and phage-based drug development. Antibiotics (Basel). 2024, 13:870. 10.3390\/antibiotics13090870","journal-title":"Antibiotics (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00012-19","article-title":"Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies","volume":"83","author":"D\u0105browska K","year":"2019","unstructured":"D\u0105browska K, Abedon ST. Pharmacologically aware phage therapy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies. Microbiol Mol Biol Rev. 2019, 83:4. 10.1128\/MMBR.00012-19","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2415","article-title":"The biofilm matrix","volume":"8","author":"Flemming HC","year":"2010","unstructured":"Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010, 8:623-33. 10.1038\/nrmicro2415","journal-title":"Nat Rev Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-017-8224-6","article-title":"Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process","volume":"101","author":"Latka A","year":"2017","unstructured":"Latka A, Maciejewska B, Majkowska-Skrobek G, Briers Y, Drulis-Kawa Z. Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol. 2017, 101:3103-19. 10.1007\/s00253-017-8224-6","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan BK","year":"2016","unstructured":"Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016, 6:26717. 10.1038\/srep26717","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14060545","article-title":"The current landscape of phage-antibiotic synergistic (PAS) interactions","volume":"14","author":"Supina BS","year":"2025","unstructured":"Supina BS, Dennis JJ. The current landscape of phage-antibiotic synergistic (PAS) interactions. Antibiotics (Basel). 2025, 14:545. 10.3390\/antibiotics14060545","journal-title":"Antibiotics (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley RT","year":"2017","unstructured":"Schooley RT, Biswas B, Gill JJ, et al.. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017, 61:10. 10.1128\/AAC.00954-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick RM","year":"2019","unstructured":"Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al.. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019, 25:730-3. 10.1038\/s41591-019-0437-z","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault P","year":"2019","unstructured":"Jault P, Leclerc T, Jennes S, et al.. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect Dis. 2019, 19:35-45. 10.1016\/S1473-3099(18)30482-1","journal-title":"Lancet Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Petrovic Fabijan A","year":"2020","unstructured":"Petrovic Fabijan A, Lin RC, Ho J, Maddocks S, Ben Zakour NL, Iredell JR. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol. 2020, 5:465-72. 10.1038\/s41564-019-0634-z","journal-title":"Nat Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner L","year":"2021","unstructured":"Leitner L, Ujmajuridze A, Chanishvili N, et al.. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021, 21:427-36. 10.1016\/S1473-3099(20)30330-3","journal-title":"Lancet Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1631359","article-title":"Regulation of phage therapy medicinal products: developments, challenges, and opportunities","volume":"15","author":"Fuerst-Wilmes M","year":"2025","unstructured":"Fuerst-Wilmes M, Respondek V, Schramm M, Lilienthal N, Buss K, Duechting A. Regulation of phage therapy medicinal products: developments, challenges, and opportunities. Front Cell Infect Microbiol. 2025, 15:1631359. 10.3389\/fcimb.2025.1631359","journal-title":"Front Cell Infect Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3523-0_6","article-title":"Bacteriophage production in compliance with regulatory requirements","volume":"2734","author":"Pirnay JP","year":"2024","unstructured":"Pirnay JP, Merabishvili M, De Vos D, Verbeken G. Bacteriophage production in compliance with regulatory requirements. Methods Mol Biol. 2024, 2734:89-115. 10.1007\/978-1-0716-3523-0_6","journal-title":"Methods Mol Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1713471","article-title":"Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections","volume":"16","author":"Fukaya-Shiba A","year":"2025","unstructured":"Fukaya-Shiba A, Ogata A, Kuribayashi R, et al.. Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. Front Pharmacol. 2025, 16:1713471. 10.3389\/fphar.2025.1713471","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2026.06.005","article-title":"Towards a reference methodology for bacteriophage susceptibility testing - position paper of the EUCAST Phage Susceptibility Testing Subcommittee","author":"Classen AY","year":"2026","unstructured":"Classen AY, Clokie MR, Giske CG, Paz RN, Pirnay JP, Resch G, Laurent F. Towards a reference methodology for bacteriophage susceptibility testing - position paper of the EUCAST Phage Susceptibility Testing Subcommittee. Clin Microbiol Infect. 2026, 10.1016\/j.cmi.2026.06.005","journal-title":"Clin Microbiol Infect"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00044-24","article-title":"Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections","volume":"37","author":"Siopi M","year":"2024","unstructured":"Siopi M, Skliros D, Paranos P, Koumasi N, Flemetakis E, Pournaras S, Meletiadis J. Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Rev. 2024, 37:e0004424. 10.1128\/cmr.00044-24","journal-title":"Clin Microbiol Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107570","article-title":"Clinical application of customized and non-customized bacteriophage therapy in patients with refractory\/resistant bacterial infections: A systematic review and meta-analysis","volume":"66","author":"Liu Y","year":"2025","unstructured":"Liu Y, Thong S, Moreira W, et al.. Clinical application of customized and non-customized bacteriophage therapy in patients with refractory\/resistant bacterial infections: A systematic review and meta-analysis. Int J Antimicrob Agents. 2025, 66:107570. 10.1016\/j.ijantimicag.2025.107570","journal-title":"Int J Antimicrob Agents"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2022.101209","article-title":"An overview of the current state of phage therapy for the treatment of biofilm-related infections","volume":"53","author":"Pires DP","year":"2022","unstructured":"Pires DP, Meneses L, Brand\u00e3o AC, Azeredo J. An overview of the current state of phage therapy for the treatment of biofilm-related infections. Curr Opin Virol. 2022, 53:101209. 10.1016\/j.coviro.2022.101209","journal-title":"Curr Opin Virol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-026-00789-7","article-title":"Giving antibiotics a second chance: evolutionary trade-offs and phage-driven restoration of antibiotic susceptibility","volume":"40","author":"W\u00f3jcicki M","year":"2026","unstructured":"W\u00f3jcicki M, Cie\u015blik M, G\u00f3rski A, Jo\u0144czyk-Matysiak E. Giving antibiotics a second chance: evolutionary trade-offs and phage-driven restoration of antibiotic susceptibility. BioDrugs. 2026, 40:623-40. 10.1007\/s40259-026-00789-7","journal-title":"BioDrugs"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbag085","article-title":"Towards accurate artificial intelligence models for strain-level phage-host prediction","volume":"27","author":"Malajczuk CJ","year":"2026","unstructured":"Malajczuk CJ, Vaitekenas A, Iszatt JJ, Stick SM, Kicic A, Karpievitch YV. Towards accurate artificial intelligence models for strain-level phage-host prediction. Brief Bioinform. 2026, 27:bbag085. 10.1093\/bib\/bbag085","journal-title":"Brief Bioinform"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/534492-beyond-antibiotics-bacteriophage-therapy-against-multidrug-resistant-pathogens-in-the-era-of-antimicrobial-resistance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:15:04Z","timestamp":1789827304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/534492-beyond-antibiotics-bacteriophage-therapy-against-multidrug-resistant-pathogens-in-the-era-of-antimicrobial-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.116535","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}